Kohlgruber A, Dezfulian M, Sie B, Wang C, Kula T, Laserson U
Nat Biotechnol. 2024; .
PMID: 38956325
DOI: 10.1038/s41587-024-02248-6.
Miliotou A, Georgiou-Siafis S, Ntenti C, Pappas I, Papadopoulou L
Curr Issues Mol Biol. 2023; 45(11):9181-9214.
PMID: 37998753
PMC: 10670245.
DOI: 10.3390/cimb45110576.
Yoo H, Harapan B
Immunol Res. 2021; 69(6):471-486.
PMID: 34554405
PMC: 8580929.
DOI: 10.1007/s12026-021-09236-x.
Liu Y, He Y
Ann Transl Med. 2021; 9(9):808.
PMID: 34268421
PMC: 8246176.
DOI: 10.21037/atm-20-5419.
Liu J, Li C, Brans T, Harizaj A, Van de Steene S, Beer T
Int J Mol Sci. 2020; 21(4).
PMID: 32102402
PMC: 7073198.
DOI: 10.3390/ijms21041540.
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
Han X, Wang Y, Wei J, Han W
J Hematol Oncol. 2019; 12(1):128.
PMID: 31783889
PMC: 6884912.
DOI: 10.1186/s13045-019-0813-7.
Applications of molecular engineering in T-cell-based immunotherapies.
McBride D, Kerr M, Wai S, Shah N
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019; 11(5):e1557.
PMID: 30972976
PMC: 7869905.
DOI: 10.1002/wnan.1557.
A Review on Electroporation-Based Intracellular Delivery.
Shi J, Ma Y, Zhu J, Chen Y, Sun Y, Yao Y
Molecules. 2018; 23(11).
PMID: 30469344
PMC: 6278265.
DOI: 10.3390/molecules23113044.
CRISPRed Macrophages for Cell-Based Cancer Immunotherapy.
Ray M, Lee Y, Hardie J, Mout R, Tonga G, Farkas M
Bioconjug Chem. 2018; 29(2):445-450.
PMID: 29298051
PMC: 6063311.
DOI: 10.1021/acs.bioconjchem.7b00768.
Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor.
Leibman R, Richardson M, Ellebrecht C, Maldini C, Glover J, Secreto A
PLoS Pathog. 2017; 13(10):e1006613.
PMID: 29023549
PMC: 5638568.
DOI: 10.1371/journal.ppat.1006613.
Dendritic cell-based immunotherapy.
Sabado R, Balan S, Bhardwaj N
Cell Res. 2016; 27(1):74-95.
PMID: 28025976
PMC: 5223236.
DOI: 10.1038/cr.2016.157.
Engineering HIV-Specific Immunity with Chimeric Antigen Receptors.
Kitchen S, Zack J
AIDS Patient Care STDS. 2016; 30(12):556-561.
PMID: 27905838
PMC: 5144863.
DOI: 10.1089/apc.2016.0239.
T-cell therapies for HIV: Preclinical successes and current clinical strategies.
Patel S, Jones R, Nixon D, Bollard C
Cytotherapy. 2016; 18(8):931-942.
PMID: 27265874
PMC: 4935558.
DOI: 10.1016/j.jcyt.2016.04.007.
Skewed Differentiation of Circulating Vγ9Vδ2 T Lymphocytes in Melanoma and Impact on Clinical Outcome.
Toia F, Buccheri S, Anfosso A, Moschella F, Dieli F, Meraviglia S
PLoS One. 2016; 11(2):e0149570.
PMID: 26915072
PMC: 4767817.
DOI: 10.1371/journal.pone.0149570.
Rapid cloning, expression, and functional characterization of paired αβ and γδ T-cell receptor chains from single-cell analysis.
Guo X, Dash P, Calverley M, Tomchuck S, Dallas M, Thomas P
Mol Ther Methods Clin Dev. 2016; 3:15054.
PMID: 26858965
PMC: 4729322.
DOI: 10.1038/mtm.2015.54.
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
Majchrzak K, Nelson M, Bailey S, Bowers J, Yu X, Rubinstein M
Cancer Immunol Immunother. 2016; 65(3):247-59.
PMID: 26825102
PMC: 5115162.
DOI: 10.1007/s00262-016-1797-6.
Gene therapy for cancer: present status and future perspective.
Amer M
Mol Cell Ther. 2015; 2:27.
PMID: 26056594
PMC: 4452068.
Th17 cells in cancer: the ultimate identity crisis.
Bailey S, Nelson M, Himes R, Li Z, Mehrotra S, Paulos C
Front Immunol. 2014; 5:276.
PMID: 24987392
PMC: 4060300.
DOI: 10.3389/fimmu.2014.00276.
Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.
Sachamitr P, Hackett S, Fairchild P
Front Immunol. 2014; 5:176.
PMID: 24860566
PMC: 4029000.
DOI: 10.3389/fimmu.2014.00176.
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Cameron B, Gerry A, Dukes J, Harper J, Kannan V, Bianchi F
Sci Transl Med. 2013; 5(197):197ra103.
PMID: 23926201
PMC: 6002776.
DOI: 10.1126/scitranslmed.3006034.